Literature DB >> 12929357

Synthesis of glycosyl derivatives as dopamine prodrugs: interaction with glucose carrier GLUT-1.

Caridad Fernández1, Ofelia Nieto, José Angel Fontenla, Emilia Rivas, María L de Ceballos, Alfonso Fernández-Mayoralas.   

Abstract

Glucosyl dopamine (DA) derivatives may represent a new class of DA prodrugs that would interact with glucose transporter GLUT-1, present in the blood-brain barrier, and generate DA in the brain. Therefore, compounds bearing the sugar moiety linked to either the amino group or the catechol ring of DA through amide, ester, carbamate, peptide or glycosidic bonds were synthesized. The behavior of the compounds as prodrugs was monitored in different media and the affinity of the glycoconjugates for the glucose carrier GLUT-1 using human erythrocytes was also studied. Most of the compounds were markedly stable in buffer and plasma, and several compounds released DA when incubated with brain extracts and the rate was related to the bond linking DA with glucose. The new glucosyl conjugates substituted at the C-6 position of the sugar were more potent inhibitors of glucose transport when compared to C-1 and C-3 substituted derivatives. This work provides structure-activity information about the interaction of substituted glucose with the GLUT-1 transporter.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12929357     DOI: 10.1039/b212066f

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  12 in total

1.  Design, synthesis and brain uptake of LAT1-targeted amino acid prodrugs of dopamine.

Authors:  Lauri Peura; Kalle Malmioja; Kristiina Huttunen; Jukka Leppänen; Miia Hämäläinen; Markus M Forsberg; Mikko Gynther; Jarkko Rautio; Krista Laine
Journal:  Pharm Res       Date:  2013-10       Impact factor: 4.200

Review 2.  Prodrug approaches for CNS delivery.

Authors:  Jarkko Rautio; Krista Laine; Mikko Gynther; Jouko Savolainen
Journal:  AAPS J       Date:  2008-02-05       Impact factor: 4.009

3.  Syntheses of dopa glycosides using glucosidases.

Authors:  Ramaiah Sivakumar; Thangavel Ponrasu; Soundar Divakar
Journal:  Glycoconj J       Date:  2008-08-19       Impact factor: 2.916

Review 4.  Targeting Transporters for Drug Delivery to the Brain: Can We Do Better?

Authors:  Elena Puris; Gert Fricker; Mikko Gynther
Journal:  Pharm Res       Date:  2022-03-31       Impact factor: 4.580

5.  p-Nitrophenyl carbonate promoted ring-opening reactions of DBU and DBN affording lactam carbamates.

Authors:  Madhuri Vangala; Ganesh P Shinde
Journal:  Beilstein J Org Chem       Date:  2016-09-26       Impact factor: 2.883

6.  The stress response factor daf-16/FOXO is required for multiple compound families to prolong the function of neurons with Huntington's disease.

Authors:  Francesca Farina; Emmanuel Lambert; Lucie Commeau; François-Xavier Lejeune; Nathalie Roudier; Cosima Fonte; J Alex Parker; Jacques Boddaert; Marc Verny; Etienne-Emile Baulieu; Christian Neri
Journal:  Sci Rep       Date:  2017-06-21       Impact factor: 4.379

Review 7.  Dopamine and Levodopa Prodrugs for the Treatment of Parkinson's Disease.

Authors:  Fatma Haddad; Maryam Sawalha; Yahya Khawaja; Anas Najjar; Rafik Karaman
Journal:  Molecules       Date:  2017-12-25       Impact factor: 4.411

8.  Current Challenges and Opportunities in Treating Glioblastoma.

Authors:  Andrea Shergalis; Armand Bankhead; Urarika Luesakul; Nongnuj Muangsin; Nouri Neamati
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

Review 9.  Strategies for Enhancing the Permeation of CNS-Active Drugs through the Blood-Brain Barrier: A Review.

Authors:  Isra' Zeiadeh; Anas Najjar; Rafik Karaman
Journal:  Molecules       Date:  2018-05-28       Impact factor: 4.411

Review 10.  Antiparkinson prodrugs.

Authors:  Antonio Di Stefano; Piera Sozio; Laura Serafina Cerasa
Journal:  Molecules       Date:  2008-01-16       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.